Commercialization support

Real-world evidence (RWE)

Discover more

Article

Real world evidence: The importance for rare disease therapies

Contact sales

We're here to answer questions and to support your commercialization needs.

Strengthen your value story with an innovative approach to RWE

Through collaboration, we support your value story by addressing research needs with real-world evidence (RWE) in North America and throughout global markets. Meet the demands of today’s payers and enhance the understanding of a product's impact on patient care and healthcare systems.

With access to more than 100 data sources and over 100,000 healthcare providers, our team knows the right questions to ask to develop an evidence portfolio that achieves your brand goals. We offer expertise in difficult-to-identify patient populations, including oncology and other rare diseases.
Our real-world evidence solutions can help you to:

  • Gain credible, valid evidence that demonstrates value, differentiates from competitors, and improves patient access.
  • Address evidentiary gaps by capturing needed data fast, efficiently, and cost-effectively.
  • Inform commercialization decision-making by demonstrating economic impact of the therapy.
  • Receive personalized support and white-glove service with an experienced and dedicated prospective studies project team.

Features and services

Generate real-world evidence across a large spectrum of criteria to further distinguish your brand. Our researchers reveal data to assist in proving disease burden, increased adherence, fewer hospitalizations, reduced physician visits, and superior safety profiles.
We design and conduct in-depth, real-world evidence studies to collect a variety of endpoints. Leverage full-service support, including protocol development, site selection and management, IRB submissions and approvals, development and maintenance of EDC tools, patient recruitment, statistical analyses, and preparation of final study reports.

Solutions

Global

PharmaLex

PharmaLex offers RWE services across global markets.

Canada

Innomar Strategies

Innomar Strategies provides real-world evidence services in Canada.

Our expertise

Utilize Cencora's extensive expertise and innovative approach to address your research objectives with the right data and methodology.
80%
of US payers leverage RWE in assessments of new technologies
120%+
use of RWE in FDA submissions since publication of RWE Evidence Program framework
90%+
client satisfaction rate

Related resources

global market access trends in 2024

Guide

Cencora’s Healthcare Landscape Outlook: Anticipating the top market access trends globally for 2025
abstract-brand-colors-texture

Guide

The essential guide to drug commercialization

Case study

Addressing an Evidentiary Gap With Real-World Prospective Studies

Discover more capabilities

Drug research and clinical development support

Streamline the drug development process and minimize risk when bringing new therapies to market with our suite of consulting and support solutions.

Patient access and adherence support

Address potential barriers to access and increase the speed-to-therapy with our suite of pharma patient support services.

Specialty logistics and warehousing

Leveraging our global network, specialized packaging, and customs expertise to ensure safe, secure storage and timely delivery worldwide.

Want more information?

We're here to answer questions and to support your commercialization needs.